Taking T-Cell Oncotheraphy Off-the-Shelf

Mo Feiyan; Mamonkin Maksim; Brenner Malcolm K.; Heslop Helen E.

首页> 外文期刊>Trends in immunology >Taking T-Cell Oncotheraphy Off-the-Shelf

【24h】

Taking T-Cell Oncotheraphy Off-the-Shelf

机译：服用T-Cell onColthelphy

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Banked allogeneic or 'off-the-shelf' (OTS) T cells from healthy human donors are being developed to address the limitations of autologous cell therapies. Potential challenges of OTS T cell therapies are associated with their allogeneic origin and the possibility of graft-versus-host disease (GvHD) and host-versus-graft immune reactions. While the risk of GvHD from OTS T cells has been proved to be manageable in clinical studies, approaches to prevent immune rejection of OTS cells are at an earlier stage of development. We provide an overview of strategies to generate OTS cell therapies and mitigate alloreactivity-associated adverse events, with a focus on recent advances for preventing immune rejection.

机译：为了解决自体细胞疗法的局限性，正在开发来自健康人类供体的储备同种异体或“现成”（OTS）T细胞。OTS T细胞疗法的潜在挑战与异基因起源、移植物抗宿主病（GvHD）和宿主抗移植物免疫反应的可能性有关。虽然OTS T细胞的GvHD风险在临床研究中已被证明是可控的，但预防OTS细胞免疫排斥反应的方法仍处于早期发展阶段。我们概述了产生OTS细胞疗法和减轻同种异体反应相关不良事件的策略，重点介绍了预防免疫排斥反应的最新进展。

著录项

来源
《Trends in immunology》 |2021年第3期|共12页
作者
Mo Feiyan; Mamonkin Maksim; Brenner Malcolm K.; Heslop Helen E.;
展开▼
作者单位

Texas Childrens Hosp Ctr Cell &

Gene Therapy Baylor Coll Med Houston TX 77030 USA;

Texas Childrens Hosp Ctr Cell &

Gene Therapy Baylor Coll Med Houston TX 77030 USA;

Texas Childrens Hosp Ctr Cell &

Gene Therapy Baylor Coll Med Houston TX 77030 USA;

Texas Childrens Hosp Ctr Cell &

Gene Therapy Baylor Coll Med Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词

相似文献

外文文献
中文文献
专利

1. Variant signaling topology at the cancer cell–T-cell interface induced by a two-component T-cell engager [J] . Dina Kouhestani, Maria Geis, Saed Alsouri, 细胞与分子免疫学：英文版 . 2021,第006期
2. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China [J] . Yanfen Feng, Huilan Rao, Yiyan Lei, 癌症（英文版） . 2017,第006期
3. CD4+ T-cell dependence of primary CD8+ T-cell response against vaccinia virus depends upon route of infection and viral dose [J] . Zhuting Hu, Michael J Molloy, Edward J Usherwood 中国免疫学杂志（英文版） . 2016,第001期
4. CD4＋ T-cell dependence of primary CD8＋ T-cell response against vaccinia virus depends upon route of infection and viral dose [J] . Zhuting Hu, Michael J Molloy, Edward J Usherwood 细胞与分子免疫学：英文版 . 2016,第001期
5. The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4＋CD25＋ regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment [J] . Jiezuan Yang, Guoping Sheng, Dangsheng Xiao, 细胞与分子免疫学：英文版 . 2016,第005期
6. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells [J] . David H. Quach, Luis Becerra-Dominguez, Rayne H. Rouce, Journal of Translational Medicine . 2019,第1期

机译：使用专为消除同种反应性T细胞而设计的病毒特异性T细胞来保护现成的细胞疗法产品的策略
7. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies [J] . Poirot Laurent, Philip Brian, Schiffer-Mannioui Cecile, Cancer research: The official organ of the American Association for Cancer Research, Inc . 2015,第18期

机译：多重基因组编辑的T细胞制造平台，用于“现成的”过继T细胞免疫疗法
8. Advances in Off-the-Shelf CAR T-Cell Therapy [J] . Reuben Benjamin MBBS MRCP FRCPath PhD Clinical advances in hematology & oncology: H&O . 2019,第3期

机译：现成的CAR T细胞疗法的进展
9. A NOVEL SCALABLE MANUFACTURING PLATFORM FOR T-CELL ACTIVATION AND EXPANSION IN ADOPTIVE T-CELL THERAPY [C] . Jian Ling Conference on advancing manufacture of cell and gene therapies . 2019

机译：适应性T细胞治疗中T细胞活化和扩展的新型可扩展制造平台
10. Label-Free CD8+ T-Cell Purification and Electroporation in Relation to Car T-Cell Therapy [D] . Ringwelski, Beth Anne. 2020

机译：无标记的CD8 + T细胞纯化和电穿孔与汽车T细胞疗法有关
11. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells [O] . David H. Quach, Luis Becerra-Dominguez, Rayne H. Rouce, 2019

机译：使用专为消除同种反应性T细胞而设计的病毒特异性T细胞来保护现成的细胞疗法产品的策略
12. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy [O] . Shoichi Iriguchi, Yutaka Yasui, Yohei Kawai, 2021

机译：一种临床应用和可扩展的方法，可从IPSC中再生T细胞进行搁板的T细胞免疫疗法
13. Evaluation of Commercial Off-the-Shelf and Government Off-the-Shelf Microclimate Cooling Systems [R] . Laprise, B. , Teal, W. , Zuckerman, L. , 2005

机译：商业现货和政府现货微气候冷却系统的评估

Taking T-Cell Oncotheraphy Off-the-Shelf

摘要

著录项

相似文献

相关主题

期刊订阅